InCarda Therapeutics touted top-line data today from a Phase I study of its InRhythm inhaled flecainide as a treatment of symptomatic acute episodes of paroxysmal atrial fibrillation.
InRhythm delivers flecainide via inhalation to get the drug to the heart through the lungs. Flecainide is already approved as an oral anti-arrhythmic drug for patients with PAF.
Get the full story at our sister site, Drug Delivery Business News.
The post InCarda touts inhaled flecainide as paroxysmal atrial fibrillation therapy appeared first on MassDevice.